There is one clinical trial.
RATIONALE: Gene therapy may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of gene therapy together with chemotherapy in treating patients with advanced solid tumors or non-Hodgkin's lymphoma.
DISEASE CHARACTERISTICS: - One of the following histologically confirmed diseases for which no curative surgical, radiotherapy, or chemotherapy programs are available and standard therapy offers, at best, a modest clinical benefit - Solid tumors - Gliomas - Non-Hodgkin's lymphoma - Primary and metastatic CNS malignancies are eligible - Evaluable or measurable disease - CD34 count at least 2.0 cells/μL - No bone marrow involvement - Histologically negative bone marrow biopsy PATIENT CHARACTERISTICS: Age: - 18 to 70 Performance status: - ECOG 0-2 Life expectancy: - At least 12 weeks Hematopoietic: - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 - Hemoglobin at least 8.5 g/dL Hepatic: - Bilirubin no greater than 1.5 mg/dL - AST and ALT less than 2.5 times normal - Prothrombin time less than 1.2 times normal Renal: - Creatinine no greater than 2.0 mg/dL Cardiovascular: - No acute cardiac disease by EKG Pulmonary: - No symptomatic pulmonary disease Other: - HIV negative - No other severe comorbid conditions - Not pregnant or nursing - Fertile patients must use effective contraception during and for 2 months after study completion PRIOR CONCURRENT THERAPY: Biologic therapy: - See Chemotherapy - No prior hematopoietic stem cell transplantation Chemotherapy: - No prior high-dose chemotherapy - Prior adjuvant chemotherapy allowed Endocrine therapy: - Not specified Radiotherapy: - No prior radiotherapy to 25% or more of bone marrow Surgery: - Not specified Other: - At least 4 weeks since prior myelosuppressive therapy DISEASE CHARACTERISTICS: - One of the following histologically confirmed diseases for which no curative surgical, radiotherapy, or chemotherapy programs are available and standard therapy offers, at best, a modest clinical benefit - Solid tumors - Gliomas - Non-Hodgkin's lymphoma - Primary and metastatic CNS malignancies are eligible - Evaluable or measurable disease - CD34 count at least 2.0 cells/μL - No bone marrow involvement - Histologically negative bone marrow biopsy PATIENT CHARACTERISTICS: Age: - 18 to 70 Performance status: - ECOG 0-2 Life expectancy: - At least 12 weeks Hematopoietic: - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 - Hemoglobin at least 8.5 g/dL Hepatic: - Bilirubin no greater than 1.5 mg/dL - AST and ALT less than 2.5 times normal - Prothrombin time less than 1.2 times normal Renal: - Creatinine no greater than 2.0 mg/dL Cardiovascular: - No acute cardiac disease by EKG Pulmonary: - No symptomatic pulmonary disease Other: - HIV negative - No other severe comorbid conditions - Not pregnant or nursing - Fertile patients must use effective contraception during and for 2 months after study completion PRIOR CONCURRENT THERAPY: Biologic therapy: - See Chemotherapy - No prior hematopoietic stem cell transplantation Chemotherapy: - No prior high-dose chemotherapy - Prior adjuvant chemotherapy allowed Endocrine therapy: - Not specified Radiotherapy: - No prior radiotherapy to 25% or more of bone marrow Surgery: - Not specified Other: - At least 4 weeks since prior myelosuppressive therapy Brain and Central Nervous System Tumors Lymphoma Unspecified Adult Solid Tumor, Protocol Specific Lymphoma Nervous System Neoplasms Central Nervous System Neoplasms Neoplasms OBJECTIVES: - Evaluate the feasibility of introducing and expressing mutant MGMT-G156A cDNA in hematopoietic progenitors taken from patients with advanced solid tumors (including gliomas) or non-Hodgkin's lymphoma using a safety modified retroviral vector MFG. - Determine the toxicity associated with reinfusion of ex vivo-transduced hematopoietic stem cells into these patients, including the detection of replication competent retrovirus. --- G156A ---
- Evaluate the feasibility of identifying mutant MGMT-G156A-transduced and O6-benzylguanine (BG)- and temzolomide-resistant hematopoietic and stromal progenitors from the bone marrow of these patients. --- G156A ---
The CD34 positive stem cells are then infected by the retroviral mutant MGMT-G156A ex vivo. --- G156A ---